ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture

As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial ...

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® ...
Fierce Biotech

Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both

It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in ...

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...

BioNTech SE: BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and combination strategy highlighted through multiple clinical ...
ascopubs.org

Journal of Clinical Oncology Podcast

Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial ...